Additional file 1 of Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013–2018
Creators: name: Acharya, Mahip
name: Zorn, Kristin K.
name: Simonson, Melinda E.
name: Bimali, Milan
name: Moore, Gary W.
name: Peng, Cheng
name: Martin, Bradley C.
Publisher: name: figshare
Year: 2022
Subjects: Medicine
Biological Sciences not elsewhere classified
Cancer
Science Policy

description: Additional File 1: (Supplementary Table 1and Supplementary Figures 1 – 37). Supplementary Table 1. Diagnosis codes used to identify mental health disorders. Supplementary Figure 1. Sample selection for the exploratory models (2nd objective of the study). Supplementary Figure 2. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in Medicaid enrollees. Supplementary Figure 3. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in Commercial plan enrollees. Supplementary Figure 4. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in State Employee plan enrollees. Supplementary Figure 5. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in Medicare enrollees. Supplementary Figure 6. Actual and predicted rates of Lynch syndrome genetic testing in Medicaid enrollees. Supplementary Figure 7. Actual and predicted rates of Lynch syndrome genetic testing in Commercial enrollees. Supplementary Figure 8. Actual and predicted rates of Lynch syndrome genetic testing in State employee plan enrollees. Supplementary Figure 9. Actual and predicted rates of Lynch syndrome genetic testing in Medicare enrollees. Supplementary Figure 10. Actual and predicted rates of Tier 2 molecular pathology procedures* in Medicaid enrollees. Supplementary Figure 11. Actual and predicted rates of Tier 2 molecular pathology procedures* in Commercial plan enrollees. Supplementary Figure 12. Actual and predicted rates of Tier 2 molecular pathology procedures* in State employee plan enrollees. Supplementary Figure 13. Actual and predicted rates of Tier 2 molecular pathology procedures* in Medicare enrollees. Supplementary Figure 14. Actual and predicted rates of any cancer genetic testing* in Medicaid enrollees. Supplementary Figure 15. Actual and predicted rates of any cancer genetic testing* in Commercial plan enrollees. Supplementary Figure 16. Actual and predicted rates of any cancer genetic testing* in State employee plan enrollees. Supplementary Figure 17. Actual and predicted rates of any cancer genetic testing* in Medicare enrollees. Supplementary Figure 18. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in men 18–64 years old. Supplementary Figure 19. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in men ≥65 years old. Supplementary Figure 20. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in women 18–64 years old. Supplementary Figure 21. Actual and predicted rates of Hereditary Breast and Ovarian Cancer (HBOC) genetic testing in women ≥65 years old. Supplementary Figure 22. Actual and predicted rates of Lynch syndrome genetic testing in men 18–64 years old. Supplementary Figure 23. Actual and predicted rates of Lynch syndrome genetic testing in men ≥65 years old. Supplementary Figure 24. Actual and predicted rates of Lynch syndrome genetic testing in women 18–64 years old. Supplementary Figure 25. Actual and predicted rates of Lynch syndrome genetic testing in women ≥65 years old. Supplementary Figure 26. Actual and predicted rates of Tier 2 molecular pathology procedures* in male enrollees &lt;18 years old. Supplementary Figure 27. Actual and predicted rates of Tier 2 molecular pathology procedures* in men 18–64 years old. Supplementary Figure 28. Actual and predicted rates of Tier 2 molecular pathology procedures* in men ≥65 years old. Supplementary Figure 29. Actual and predicted rates Tier 2 molecular pathology procedures* in female enrollees &lt;18 years old. Supplementary Figure 30. Actual and predicted rates of Tier 2 molecular pathology procedures* in women 18–64 years old. Supplementary Figure 31. Actual and predicted rates of Tier 2 molecular pathology procedures* in women ≥65 years old. Supplementary Figure 32. Actual and predicted rates of any cancer genetic testing* in male enrollees &lt;18 years old. Supplementary Figure 33. Actual and predicted rates of any cancer genetic testing* in men 18–64 years old. Supplementary Figure 34. Actual and predicted rates of any cancer genetic testing* in men ≥65 years old. Supplementary Figure 35. Actual and predicted rates of any cancer genetic testing* in female enrollees &lt;18 years old. Supplementary Figure 36. Actual and predicted rates of any cancer genetic testing* in women 18–64 years old. Supplementary Figure 37. Actual and predicted rates of any cancer genetic testing* in women.